Being able to test Fable 5 until June 22nd, only to have it removed from the plans, feels like getting a sneak peek and then having the food taken away from the table.

But from a business perspective, it makes perfect sense for Anthropic and its upcoming IPO: It demonstrates how advanced Anthropic is, how good its models are (the blog post refers to biology and research), and especially in the enterprise sector, companies often want the best model, which is also more expensive.

Therefore, it will generate even more revenue for the company.

But admittedly, the fact that Anthropic was able to accelerate "internal protein design experts aspects of the drug design process by around ten times" is extremely impressive.

We are once again on the cusp of accelerated science. The next few years are going to be crazy.